Three studies presented today at the Society of NeuroInterventional Surgery’s (SNIS) 22nd Annual Meeting discussed whether ...

Polycystic Ovary Syndrome or PCOS affects millions of women in the United States. There is currently no standard treatment for it. Weight loss drugs l ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Some adults using weight-loss drugs like Mounjaro have complained no longer having the stomach for alcohol is one of the side effects of the jab.

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

A new study has found that older adults and women taking the weight-loss drug semaglutide may lose more muscle than others, ...